These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19947815)

  • 21. Incretins and their role in the management of diabetes.
    Frias JP; Edelman SV
    Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
    Hansen KB; Knop FK; Holst JJ; Vilsbøll T
    Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.
    Russell-Jones D
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):137-40. PubMed ID: 19041364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Aug; 80(3):396-401. PubMed ID: 20417187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
    Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide: clinical pharmacology and considerations for therapy.
    Sisson EM
    Pharmacotherapy; 2011 Sep; 31(9):896-911. PubMed ID: 21923591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness.
    Madsen K; Knudsen LB; Agersoe H; Nielsen PF; Thøgersen H; Wilken M; Johansen NL
    J Med Chem; 2007 Nov; 50(24):6126-32. PubMed ID: 17975905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sustained release and pharmacologic evaluation of human glucagon-like peptide-1 and liraglutide from polymeric microparticles.
    Icart LP; Souza FG; Lima LMTR
    J Microencapsul; 2019 Dec; 36(8):747-758. PubMed ID: 31594428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs.
    Sjöholm Å
    Pharmaceuticals (Basel); 2010 Mar; 3(3):764-781. PubMed ID: 27713278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo.
    Fremaux J; Venin C; Mauran L; Zimmer RH; Guichard G; Goudreau SR
    Nat Commun; 2019 Feb; 10(1):924. PubMed ID: 30804332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics.
    Jacobsen LV; Flint A; Olsen AK; Ingwersen SH
    Clin Pharmacokinet; 2016 Jun; 55(6):657-72. PubMed ID: 26597252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.